{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-276930","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.944113+00:00","generated_at":"2026-06-22T08:54:04.953167+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Akebia Q3 Auryxia revenue up 14.9% to $42.2M; files FDA dispute for vadadustat","bullets":["Net product revenue $42.2M (+14.9% YoY); total revenue $49.0M vs $48.8M YoY.","Net loss $51.9M vs $59.5M YoY; cash $144.8M, sufficient for at least 12 months.","Filed Formal Dispute Resolution Request with FDA over vadadustat CRL; response expected by end-2022.","Retired $33M of Pharmakon debt; 2022 Auryxia revenue guidance reaffirmed at $170-175M.","Assumed EU marketing application for vadadustat; EMA decision expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-276930","json":"https://secwatch.observer/filing/0001193125-22-276930.json","markdown":"https://secwatch.observer/filing/0001193125-22-276930.md","text":"https://secwatch.observer/filing/0001193125-22-276930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522276930/0001193125-22-276930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522276930/d402663d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:54:04.953167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c128a60c3f0a760f932aaf31dbc250531fe2376","claim":"Akebia Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $49.0 million.","evidence_excerpt":"net price per pill puts us in a position to affirm our 2022 net product revenue guidance for Auryxia of $170 - $175 million.” Financial Results • Revenues: Total revenue was $49.0 million in the third quarter of 2022 compared to $48.8 million for the third quarter of 2021. • Net product revenue was $42.2 million in the third quarter of 2022 compared to $36.8","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522276930/0001193125-22-276930-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$49.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}